Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
about
Targeted therapies in sarcomas: challenging the challengeThe crosstalk of mTOR/S6K1 and Hedgehog pathwaysPresent Advances and Future Perspectives of Molecular Targeted Therapy for OsteosarcomaThe PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challengesThe adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapyMolecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway BlockadeDexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialThe role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysisA phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumoursMetastatic perivascular epithelioid cell tumor responding to mammalian target of rapamycin inhibition.Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013.Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.MicroRNA-100 promotes the autophagy of hepatocellular carcinoma cells by inhibiting the expression of mTOR and IGF-1R.New therapeutic targets in soft tissue sarcoma.MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancerInhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat modelCan we unlock the potential of IGF-1R inhibition in cancer therapy?Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.Rapid optimization and prototyping for therapeutic antibody-like molecules.Emerging therapies for adult soft tissue sarcoma.Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and ExpectationsSuppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cellsAnti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls.The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody CixutumumabIGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitorsAdvances in sarcoma genomics and new therapeutic targets.New developments in mammalian target of rapamycin inhibitors for the treatment of sarcomaSystemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approachesTreating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus.
P2860
Q21285014-7A6E44B0-B6DF-4D48-81C7-1A6D4DA339EDQ24308749-D16233E4-08B1-4122-8ED1-801DE39A9181Q26750631-77879559-C642-4868-BBEF-A17FD73B8AAAQ26851852-39D6EA2A-69AA-4C37-937E-8E919BC37179Q27000467-3E9BEF3A-2F34-48FB-9B4F-8D965B026E43Q28088432-2843B24C-43C9-45D1-AE6F-A3E6C6F2C0C9Q28829762-96FB620D-C60E-4B40-BCC1-937618387F4AQ33276109-FD9DADF3-65FC-4ACA-9F03-2C718EEF42F0Q33400495-35A3BCF2-6EA2-45CC-B256-D3FB89F295D4Q33406371-BFF07DB2-D03D-4B99-8DF3-7B13759A0DCFQ33407600-9A4BFEA8-6A10-42AA-B4A1-D6CC56850D7EQ33418329-6E98E6D5-8707-44FF-98ED-C1D20CD12C44Q33433105-58CA3FD1-B8D6-45D2-A80A-112A56940111Q33841595-8DE44D9D-3754-4A6C-84F9-665A7E213AF8Q34038664-5A4041B3-850C-48AE-927C-F64702F17741Q34110523-7578B269-5978-4565-873D-DC1C26D5BF6FQ34147910-BE67BA58-E7AC-48C7-9C82-F5E453AA9A47Q34227658-14584D33-F351-4BF9-B0B5-82B9B403184AQ34267924-411379EB-FF85-44C9-B130-31017F4A5E4BQ34282551-5855438A-8B1C-4637-93FA-18B2F28CA8CAQ34325616-29C1ED2C-9DE3-43ED-A61C-1D6CF6167F4DQ34336988-EC2A37A9-03FC-4A35-8D94-32DF963CD02FQ34391968-31C312A0-3BD9-4C77-90A1-9BFFEFCD81C1Q34483665-8A47781C-A687-49CE-B8D0-4AD6DEB2FFD0Q34499662-BBDD1134-618E-4506-B396-A64E988A0CBAQ34532397-4ED84F94-0FAA-41D4-8356-D9BE7885FC5CQ34580658-9DEED8A7-2C05-40F3-A9F2-8A2005719902Q34659806-A39B2002-3BF1-4791-9DEB-2A23EFE8107AQ35013284-E094D270-B21F-47A3-AA65-BA34458E330AQ35110805-46E4647E-8D06-46F4-A335-88DD889514A4Q35237773-23515BF5-FD46-43CE-A727-2B44B6A14F8AQ35609517-9D0FF638-7A61-4D44-AA37-4124BB17BA98Q35810171-DB0C0271-A1F7-42EB-B3FD-D9DB1DCD5EB8Q35820595-018B7DA8-3155-43B6-8BF8-141F61E7CB52Q35836632-DCDBB5B7-341A-480A-8563-B7F2BF03820CQ35838565-2C6BF6B3-05AD-41EF-A69B-7EA1BC1F491AQ35993346-F7B5BBEB-80C4-4D51-9B50-FDDA0D29D412Q36144084-8EA358D3-1BAF-4DD9-BAAA-6AEEDB6268EAQ36144210-675A747D-54F4-48C5-9F9D-A254D0505B4CQ36191321-633DA4A7-D4A6-492D-8AAE-5198B9F7E2AB
P2860
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Combination mTOR and IGF-1R in ...... rcomas and other solid tumors.
@ast
Combination mTOR and IGF-1R in ...... rcomas and other solid tumors.
@en
Combination mTOR and IGF-1R in ...... rcomas and other solid tumors.
@nl
type
label
Combination mTOR and IGF-1R in ...... rcomas and other solid tumors.
@ast
Combination mTOR and IGF-1R in ...... rcomas and other solid tumors.
@en
Combination mTOR and IGF-1R in ...... rcomas and other solid tumors.
@nl
prefLabel
Combination mTOR and IGF-1R in ...... rcomas and other solid tumors.
@ast
Combination mTOR and IGF-1R in ...... rcomas and other solid tumors.
@en
Combination mTOR and IGF-1R in ...... rcomas and other solid tumors.
@nl
P2093
P1476
Combination mTOR and IGF-1R in ...... rcomas and other solid tumors.
@en
P2093
Andrew J Wagner
Geoffrey I Shapiro
George D Demetri
James E Butrynski
Jeffrey A Morgan
Judith Manola
Nicole Jederlinic
Nikhil Ramaiya
Richard Quek
P304
P356
10.1158/1078-0432.CCR-10-2621
P407
P577
2010-12-22T00:00:00Z